EADV 2026 data highlight dupilumab’s effects on growth, quality of life, disease control, and itch across multiple dermatologic diseases.
|Articles|May 1, 2001
Consider PDR a reference source, not legal standard
Dear Editor: Through the past few years, several dermatologists have addressed the relevance of the Physician's Desk Reference. Ergo, I wish to share my own writings on this topic.
Advertisement
Advertisement
Related to this article
The FDA approval, based on 36-week data from the phase 3 BRAVE-AA-PEDS trial, extends baricitinib access to patients as young as 12 years old with severe alopecia areata.
The designation marks the first FDA Fast Track status granted to a therapy for peeling skin syndrome, which currently has no approved treatment.
Advertisement
Advertisement
Trending on Dermatology Times
1
EADV 2026 Day 1: Late-Breaking Data, Emerging Therapies, and New Directions in Dermatology
2
EADV 2026 Day 2: Long-Term AD Data, GLP-1 Nail Findings, and Emerging Treatments Take Center Stage
3
Tulisokibart Meets Primary Endpoint in Phase 2b Hidradenitis Suppurativa Trial
4
Repigmentation With Upadacitinib Continues Through Week 76 in Non-Segmental Vitiligo
5